TURALIO™
Phase 1Small molecule
Daiichi SankyoTURALIO™ is one of 34 small molecule programs targeting Hepatotoxicity. It is currently in Phase 1.
3
Indications
2
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Neurofibromatosis Type 1
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Afinitor
NovartisApproved
Verzenio
Eli LillyApproved
Levulan
BBiomed Industries, Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Koselugo
AstraZenecaPhase 2
Cysteine Hydrochloride
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatotoxicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TURALIO™. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company